| P50 | author | Guy Caljon | Q37320107 |
| P2093 | author name string | Louis Maes | |
| | Paul Cos | |
| | Peter Delputte | |
| | Sarah Hendrickx | |
| | Dorien Mabille | |
| | Magali Van den Kerkhof | |
| P2860 | cites work | Development and characterization of paromomycin-resistant Leishmania donovani promastigotes | Q77352855 |
| | Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis | Q28271849 |
| | Single-dose liposomal amphotericin B for visceral leishmaniasis in India | Q28272916 |
| | Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance | Q28285948 |
| | Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol | Q28483977 |
| | Leishmania donovani develops resistance to drug combinations | Q28484463 |
| | Miltefosine and antimonial drug susceptibility of Leishmania Viannia species and populations in regions of high transmission in Colombia | Q28539068 |
| | In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis | Q28540828 |
| | Different Mutations in a P-type ATPase Transporter in Leishmania Parasites are Associated with Cross-resistance to Two Leading Drugs by Distinct Mechanisms | Q28554770 |
| | Epidemiology of visceral leishmaniasis | Q33583456 |
| | In vitro and in vivo interactions between miltefosine and other antileishmanial drugs | Q34301638 |
| | Injectable paromomycin for Visceral leishmaniasis in India | Q34639916 |
| | In Vivo Selection of Paromomycin and Miltefosine Resistance in Leishmania donovani and L. infantum in a Syrian Hamster Model | Q35859984 |
| | Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. | Q36645795 |
| | Therapeutic options for visceral leishmaniasis | Q37333942 |
| | Treatment failure and miltefosine susceptibility in dermal leishmaniasis caused by Leishmania subgenus Viannia species. | Q37544280 |
| | Laboratory confirmed miltefosine resistant cases of visceral leishmaniasis from India | Q37615730 |
| | Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani | Q37712969 |
| | The treatment of visceral leishmaniasis: safety and efficacy | Q38261232 |
| | Lack of correlation between the promastigote back-transformation assay and miltefosine treatment outcome | Q39063747 |
| | Efficacy and safety of single-dose liposomal amphotericin B for visceral leishmaniasis in a rural public hospital in Bangladesh: a feasibility study | Q39262437 |
| | Mechanism of amphotericin B resistance in clinical isolates of Leishmania donovani | Q39436217 |
| | The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. | Q39614531 |
| | The in vitro leishmanicidal activity of hexadecylphosphocholine (miltefosine) against four medically relevant Leishmania species of Brazil | Q39731039 |
| | Drug resistance in leishmaniasis | Q41271991 |
| | In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences | Q41844113 |
| | Leishmania resistance to miltefosine associated with genetic marker | Q42573934 |
| | Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum | Q46921246 |
| | Immunomodulatory effect of picroliv on the efficacy of paromomycin and miltefosine in combination in experimental visceral leishmaniasis | Q51771774 |
| | Evidence of a drug-specific impact of experimentally selected paromomycin and miltefosine resistance on parasite fitness in Leishmania infantum. | Q53120855 |
| | Intracellular amastigote replication may not be required for successful in vitro selection of miltefosine resistance in Leishmania infantum. | Q53541333 |
| | Comparison of short-course multidrug treatment with standard therapy for visceral leishmaniasis in India: an open-label, non-inferiority, randomised controlled trial | Q56804080 |
| | Kala-azar elimination programme in India | Q64132519 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | miltefosine | Q411787 |
| | paromomycin | Q415625 |
| | Leishmania infantum | Q1950789 |
| | drug resistance | Q12147416 |
| P304 | page(s) | e0005620 | |
| P577 | publication date | 2017-05-15 | |
| P1433 | published in | PLoS Neglected Tropical Diseases | Q3359737 |
| P1476 | title | Combined treatment of miltefosine and paromomycin delays the onset of experimental drug resistance in Leishmania infantum | |
| P478 | volume | 11 | |